Heart failure & cardiomyopathies
Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial
Study context
- Population
- Heart failure (HF) patients post-acute myocardial infarction (MI) with LVEF ≤45% and elevated N-terminal pro-B-type natriuretic peptideplanned
- Participants
- 280 participants
- Planned comparison
- CDR132L 5 or 10 mg/kg vs placebo, in addition to standard of care
- Primary endpoint
- Left ventricular (LV) end-systolic volume index
- Follow-up
- 6 months
Methodological detailsPhase 2, multicentre, parallel, 3-arm, placebo-controlled, 6-month double-blind treatment period, 6-month open-label observation period
- Phase 2
- Multicentre
- Parallel
- 3-arm
- Placebo-controlled
- 6-month double-blind treatment period
- 6-month open-label observation period
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial. Eur J Heart Fail. Published 25 January 2024. doi:10.
Summarised from the published abstract; every number is checked against it